01—Abstract
Summary
Summary of the 10-Q filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported solid financial results for the second quarter and first half of 2026, demonstrating continued revenue growth driven primarily by its collaboration with Sanofi, particularly strong performance from Dupixent.
Total revenues increased by 15.2% for the quarter and 17.6% for the six months, reaching $4,290.7 milliona and $7,896.1 million respectively. Net income for the quarter was $1,296.9 million, a slight decrease from the prior year's $1,391.6 million, resulting in diluted earnings per share of $12.23, down from $12.81. For the first half of the year, net income was $2,024.1 million, a decrease from $2,200.3 million in the prior year, with diluted EPS of $18.95 compared to $20.02.
Despite the slight dip in profitability on a per-share basis, the company's balance sheet remains strong, with total assets growing to $41.7 billionb. The company continued its commitment to shareholder returns through dividends and share repurchases, signaling confidence in its future performance.
02—Key points
Key Highlights
- Total revenues for Q2 2026 grew 15.2% year-over-year to $4.3 billion, driven by a substantial increase in collaboration revenue, largely from the Sanofi partnership.
- Net income for Q2 2026 was $1.3 billion, leading to diluted EPS of $12.23, a decrease from the prior year's $13.24, reflecting increased operating expenses.
- For the first six months of 2026, total revenues increased 17.6% to $7.9 billion, with net income at $2.0 billion and diluted EPS of $18.95.
- Net product sales saw a modest increase of $11.4 million in Q2, with growth in EYLEA HD and Libtayo offsetting a decline in EYLEA sales due to competitive pressures and the transition to EYLEA HD.
- Sanofi collaboration revenue surged by 73.1% in Q2 to $2.17 billion, primarily due to strong Dupixent sales and a growing profit share percentage.
- Bayer collaboration revenue decreased by 33% in Q2 to $276.2 million, reflecting lower EYLEA sales outside the U.S.
- The company repurchased approximately $1.74 billion of its common stock during the first half of 2026, demonstrating a commitment to returning capital to shareholders.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 30, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $4.29B$3.68B | +16.7% |
| R&D Expenses | $1.63B$1.42B | +14.8% |
| SG&A Expenses | $662.10M$634.20M | +4.4% |
| Operating Expenses | $3.00B$2.60B | +15.5% |
| Operating Income | $1.29B$1.08B | +19.8% |
| Net Income | $1.30B$1.39B | −6.8% |
| EPS (Basic) | $12.62$13.24 | −4.7% |
| EPS (Diluted) | $12.23$12.81 | −4.5% |
| Shares Outstanding (Basic) | 102.80M105.10M | −2.2% |
| Shares Outstanding (Diluted) | 106.00M108.60M | −2.4% |
05—Questions
Frequently Asked Questions
What drove the revenue growth in the second quarter of 2026?
Regeneron's revenue growth in Q2 2026 was primarily driven by a significant increase in collaboration revenue, largely stemming from its partnership with Sanofi. This growth was fueled by strong sales of Dupixent, resulting in a higher share of profits for Regeneron.
How did EYLEA sales perform in the quarter?
Net product sales for EYLEA in the U.S. declined in Q2 2026 compared to the prior year, primarily due to ongoing competitive pressures and the market transition from EYLEA to the newer EYLEA HD. While EYLEA HD sales saw an increase, the overall EYLEA franchise experienced a net decrease in U.S. sales.
What is the company's approach to shareholder returns?
Regeneron continues to return capital to shareholders through regular cash dividends and share repurchases. During the first half of 2026, the company repurchased approximately $1.74 billion of its common stock and declared quarterly cash dividends, indicating a commitment to enhancing shareholder value.
Are there any significant legal or regulatory issues impacting the company?
Regeneron is involved in various legal proceedings, including patent infringement lawsuits related to EYLEA and other products. While the company believes it has strong defenses, adverse outcomes in these matters could potentially impact its financial results or business operations.
06—Continue